Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group
Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group
复制标题
DOI：
10.1016/j.ygyno.2007.04.007
复制
发表时间：
2007-08-01
影响因子：
4.7
通讯作者：
O'Connor, Dennis
中科院分区：
文献类型：
--
作者：
Eddy, Gary L.;Bundy, Brian N.;O'Connor, Dennis
客观的。进行了一项随机 III 期试验，以确定根治性子宫切除术和盆腔/主动脉旁淋巴结切除术 (RHPPL) 之前的新辅助化疗 (NACT) 是否可以改善无进展生存期 (PFS) 和总生存期 (OS) 以及可手术性，同时毒性水平可接受。两种治疗方案均针对特定的手术/病理危险因素规定了辅助放射治疗。方法。符合资格的患者需要患有巨块FIGO IB期宫颈癌、肿瘤直径>= 4 cm、足够的骨髓、肾和肝功能以及体能状态
Objective. A randomized phase Ill trial was conducted to determine if neoadjuvant chemotherapy (NACT) prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy (RHPPL) could improve progression-free survival (PFS) and overall survival (OS), as well as operability, with acceptable levels of toxicity. Adjuvant radiation therapy was prescribed for specific surgical/pathological risk factors for both regimens.Methods. Eligible patients were required to have bulky FIGO Stage IB cervical cancer, tumor diameter >= 4 cm, adequate bone marrow, renal and hepatic function, and performance status